A ll the noninvasive techniques in current use are notsufficiently able to identify primary tumors and even unable todefine the extent of metastatic spread.Cu rr ently, positron emission tomography/computertomography (PET/CT) are more and more widely available andtheir application with 18F-fluorodeoxyglucose (18F-FDG) inoncology has become one of the standard imaging modalities indiagnosing and staging of tumors, and monitoring thetherapeutic efficacy in malignancies. PET/CT with 18F-FDG asa radiotracer may further enhance the hepatic malignancydiagnostic algorithm by accurate diagnosis, staging, restagingand evaluating its biological characteristics, which can benefitthe patients suffering from hepatic metastases, hepatocellularcarcinoma and cholangiocarcinoma.